Are OM insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies OM leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Stock Ratings / Health Care / OM / insiders

HYPR (38) ECOR (29) STXS (22) NRXS (36) ⌘ Pro Terminal →

Outset Medical Inc. (OM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$4.03 -3.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.99

Outset Medical Inc. (OM) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $75.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OM Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Outset Medical Inc. (NASDAQ: OM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $4.03 (-3.82% 1D, market cap $75.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, OM ranks #638 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OM compare to HYPR and ECOR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), OM carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 39.1%, and ROIC of -28.0%. By comparison, HYPR (Hyperfine Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $76.1M) and ECOR (electroCore Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M). Among the 5-stock peer group, OM leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OM?

▼

Per OM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001484612), Outset Medical Inc. generated $119.5M in revenue (+5.1% YoY), -$81.7M in net income, and -$47.1M in free cash flow against $264.5M in total assets and $96.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.99 (-0.88%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (34/100 Composite)

🔍 WHY OM SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 39.1% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$4.06+3.9% Next Q

Q2 (-2Q)

Grade E$4.22+2.8% Next Q

Q3 (-1Q)

Grade E$4.34-7.1% Next Q

Current

Grade E$4.03-8.7% Hist 90D α

Trajectory: D (42) → E (34)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OM currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.72) and Max Pain ($4.23) forces dealer call-delta covering toward $13.94.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “OM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 34%NO 66%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

OM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (OM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on OM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OM)

✓Walkthrough of OM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -6.93%▼ DESCENDING CHANNEL

2026-11-03O $4.19H $4.19L $4.03C $4.03VOL 81.5K

RES: $4.41SUP: $2.23SMA50: $3.72SMA200: $4.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OM Butterfly Map → + Track OM →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +5.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OM)

Health Care Rank #638 of 1015 ⚔️ HYPR vs OM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OM vs. HYPR, ECOR, STXS, NRXS)

Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Outset Medical Inc. (OM) ranks #638 by composite RQD confidence (34/100, grade E) and #687 by equity capitalization ($75.8M). Within this direct 5-issuer industry benchmark cohort, OM leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with OM at 34/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OM ACTIVE Outset Medical Inc.	E	34/100	—	39.1%	-28.0%	-3.82%	$75.8M	Benchmark Subject
HYPR Hyperfine Inc. (Class A)	D-	38/100	—	49.8%	-35.0%	-3.50%	$76.1M	/hypr-vs-om →
ECOR electroCore Inc.	E	29/100	—	86.8%	-35.0%	-7.27%	$67.8M	/ecor-vs-om →
STXS Stereotaxis Inc.	E	22/100	—	52.7%	-35.0%	-5.21%	$86.4M	/stxs-vs-om →
NRXS Neuraxis Inc.	D-	36/100	—	84.2%	-35.0%	-5.56%	$89.5M	/nrxs-vs-om →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001484612 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Outset Medical Inc. (OM) reported GAAP revenue of $119.5M (+5.1% vs. FY2024 revenue of $113.7M , and -8.4% cumulative change since FY2023) , GAAP net income of -$81.7M, operating cash flow of -$46.3M, and free cash flow of -$47.1M (+59.8% YoY). On the balance sheet, OM closed FY2025 with $264.5M in total assets against $96.2M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$119.5M	-$81.7M	-$46.3M	-$47.1M	$264.5M	$96.2M
FY2024 (FY)	2024-12-31	$113.7M	-$128.0M	-$116.3M	-$117.2M	$275.8M	$197.4M
FY2023 (FY)	2023-12-31	$130.4M	-$172.8M	-$131.4M	-$131.4M	—	—

3. OM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does OM compare to HYPR and ECOR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for OM?

Where is OM trading relative to its 50-day, 200-day, and 52-week technical levels?

OM last traded at $4.03 (-3.82% on volume of 81,505 shares), positioning the stock +8.33% above its 50-day simple moving average ($3.72) and -2.66% below its 200-day simple moving average ($4.14). Across its 52-week range of $2.84 to $13.28, OM sits at the 11.4% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.53 to $4.53).

Direct Sub-Reports: OM RQD Cockpit OM 12M Forecast OM Earnings & Move OM Dividends & DRIP OM Insiders & 13F OM Whale Options OM Profit Sankey OM News & Why

ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

OM — Outset Medical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Outset Medical Inc. (OM) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.03 (-3.82% 1D, market capitalization $75.8M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -28.0%, gross margin of 39.1%, operating margin of -55.8%, and free cash flow yield of —.
Whale 13F & Options Flow (7/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of 0.76x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Outset Medical Inc. (OM) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry..1B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Outset Medical Inc. (OM) reported $119.5M in annual revenue (up from $113.7M in FY2024, +5.1% YoY) and -$81.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($130.4M revenue, -$172.8M net income) through FY2025, OM scaled operating cash flow to -$46.3M and free cash flow to -$47.1M, backed by $264.5M in total assets against $96.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $2.84 – $13.28 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -55.8% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), OM carries a macro regime beta of 1.00 and gross margin of 39.1%.

Key Question #1: Can OM sustain or expand its -55.8% operating margin and -28.0% ROIC against Biotechnology: Electromedical & Electrotherapeutic Apparatus peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $119.5M and free cash flow of -$47.1M, how will capital allocation balance growth reinvestment against $96.2M in total debt?
Key Question #3: How sensitive is OM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Outset Medical Inc. (OM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OM Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Outset Medical to Participate in the 2026 Stifel Healthcare Conference

Yahoo Finance report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

Full Transcript: Outset Medical Q2 2026 Earnings Call

Benzinga report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

TradingView report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE scanx.trade • 1d ago

Outset Medical to report Q3 2026 results on November 4

scanx.trade report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Reasons to Retain Hims & Hers Stock in Your Portfolio for Now

The Globe and Mail report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 1d ago

Despite Fast-paced Momentum, RXO (RXO) Is Still a Bargain Stock

Yahoo Finance report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH www.dars.gov.et • 1d ago

Outset (OM) Stock Analysis: -2.70% Down — Bearish Signals to Watch 2026-10-16 - Spring Pattern

www.dars.gov.et report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago

Outset Medical (OM) Trades Flat at $4.05 as Traders Watch $4.25 Resistance - Unusual Put Volume

https://www.dars.gov.et/ report covering Outset Medical Inc. (OM) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OM Bull vs. Bear Conversation Board — What's Your Call at $4.03?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OM 🐻 33% BEARISH CONVICTION

QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $4.76 (+18.1%)

📌 Pinned Debate

The stock trades at $4.19 after falling from a $13.28 52-week high, and the rating's whale 13F flow pillar cites institutional accumula

Here is why I am bullish on OM here at $4.03: The stock trades at $4.19 after falling from a $13.28 52-week high, and the rating's whale 13F flow pillar cites institutional accumulation.. Compare OM's -55.8% operating margin and -28.0% ROIC against the rest of Biotechnology: Electromedical & Electrotherapeutic Apparatus. As long as cash conversion holds up, dips toward $3.83 are getting bought.

CapAlloc_Nerd 🐂 BULL

@CreditSpread_Watch Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Electromedical & Electrotherapeutic Apparatus. If gross margin (39.1%) holds, EPS grows into the multiple faster than bears think.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $3.14 (-22.1%)

Spot @ $4.03

ROIC of -28%, an FCF yield of 0%, and FY 2025 free cash flow of -$47.1M show the business is not currently generating cash.

Careful chasing OM at $4.03. ROIC of -28%, an FCF yield of 0%, and FY 2025 free cash flow of -$47.1M show the business is not currently generating cash.. Gross margin is 39.1%, but operating margin is -55.8%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.14 on multiple compression.